Tesofensine: Research Overview, Purity and Sourcing

The single most consequential document in tesofensine's published history isn't a trial result. It's the expression of concern that The Lancet attached to the compound's headline obesity trial in 2013 (PubMed), published in the same period as separate correspondence on under-reporting of adverse effects in that programme (PubMed).

Our team catalogues research compounds for laboratory work, and tesofensine is the one we field the most questions about with the least accurate information attached to it. So here's the literature as it actually stands: mechanism, what the studies found, what the critics flagged, how long the molecule persists, and how a vial earns a place in a study.

What is tesofensine?

Tesofensine (development code NS2330) is a synthetic small molecule that inhibits the reuptake of three neurotransmitters at once: dopamine, noradrenaline and serotonin. It was first investigated for neurodegenerative conditions, then redirected toward obesity research after unexpected weight loss appeared in those earlier trials. It holds no marketing authorisation anywhere.

Here's the misconception worth clearing immediately: tesofensine is not a peptide. It's a phenyltropane-derived small molecule with no amino-acid backbone, which means almost nothing about peptide handling, reconstitution chemistry or cold-chain logic transfers directly to it. The term sticks because tesofensine sits in the same research-chemical supply channel as peptides and gets catalogued alongside them. This page covers the receptor mechanism, the actual trial and preclinical record, the adverse-effect controversy, reported pharmacokinetics, and the verification steps that separate a usable vial from an unusable one.

Why does the triple-reuptake mechanism matter more than the weight-loss headline?

Tesofensine blocks the dopamine transporter (DAT), the noradrenaline transporter (NET) and the serotonin transporter (SERT), which means synaptic concentrations of all three monoamines stay elevated longer than they otherwise would. That triple action is what distinguishes it from the selective reuptake inhibitors most people are familiar with, and it's the reason the compound has been discussed in broader reviews of monoamine pharmacology and personalised psychiatric medicine (PubMed).

The appetite-relevant part of the mechanism is more specific than general stimulation. Work in diet-induced obese rats reported that tesofensine produced appetite suppression through indirect stimulation of alpha-1 adrenoceptor and dopamine D1 receptor pathways, rather than by acting directly on those receptors (PubMed). That distinction matters for anyone designing a receptor-blockade experiment, because blocking the transporter and blocking the downstream receptor produce different readouts entirely.

A 2024 study in PLoS One added a circuit-level layer: tesofensine silenced GABAergic neurons in the hypothalamus of the animal model studied (PubMed). Those neurons form part of the lateral hypothalamic feeding circuitry, so silencing them is a plausible upstream explanation for reduced food-seeking behaviour that doesn't depend on peripheral metabolism at all.

Researchers tracking the individual transporter arms often compare notes on the dopamine reuptake literature, the serotonergic component and the separate question of whether any thermogenic signal is attributable to the compound rather than to reduced intake. In our experience fielding researcher questions, that last distinction is the one most often collapsed in secondary write-ups.

What does the published tesofensine research actually report?

The tesofensine literature splits cleanly into three buckets: neurology trials, obesity work, and preclinical animal studies. The neurology arm came first. A 2008 report in Obesity described weight loss produced by tesofensine in patients with Parkinson's or Alzheimer's disease (PubMed), an observation made during studies that were not designed to measure body weight as a primary outcome. The ADVANS study, published in Archives of Neurology the same year, evaluated tesofensine in patients with advanced Parkinson disease and motor fluctuations (PubMed).

That accidental finding redirected the whole programme. A 2009 review in Current Opinion in Investigational Drugs surveyed tesofensine's development as a monoamine reuptake inhibitor being pursued for obesity (PubMed), which remains a useful snapshot of where the compound sat before the later controversy.

The preclinical record is where the mechanistic detail lives. A 2013 study in Pharmacology, Biochemistry and Behavior reported that tesofensine induced appetite suppression and weight loss in diet-induced obese rats with reversal of low forebrain dopamine levels (PubMed). That framing is important and routinely lost: the animal model studied had depressed baseline dopamine tone, and tesofensine restored it rather than pushing it above normal.

Tesofensine research into appetite endpoints is frequently cross-referenced against AOD-9604 work, and the recurring question of whether tesofensine affects fat oxidation independently of intake reduction is still unresolved in the published animal data. Laboratories formalising their approach tend to start from documented research practices rather than improvising endpoints.

What does the literature report about tesofensine side effects and open questions?

The reported adverse-effect profile of tesofensine follows directly from its mechanism: monoamine reuptake inhibition across dopamine, noradrenaline and serotonin produces cardiovascular and central nervous system effects, with elevated heart rate and blood pressure, sleep disturbance, dry mouth and mood changes appearing in the trial correspondence record. Two 2009 letters in The Lancet under the heading 'Tesofensine and weight loss' debated the trial findings and their interpretation (PubMed and PubMed).

The more serious signal came four years later. The Lancet published correspondence specifically titled 'Under-reporting of adverse effects of tesofensine' (PubMed), and the journal issued an expression of concern regarding the trial on body-weight loss, body composition and quality of life in obese patients (PubMed). An expression of concern is not a retraction, but it is a formal editorial signal that the published record may not be complete.

The honest summary of the unknowns: there is no long-horizon human safety dataset for tesofensine, no published cardiovascular outcomes trial, and no regulatory review that resolved the adverse-event reporting questions. Anyone citing tesofensine efficacy figures without also citing the expression of concern is presenting half the record.

Researchers building a defensible paper trail around these gaps generally document every tesofensine research step from the start, because retrofitting provenance after the fact rarely survives peer review.

How long does tesofensine stay in circulation?

The defining pharmacokinetic feature of tesofensine is an unusually long elimination half-life for a small molecule. The figure most frequently repeated in secondary pharmacology literature is approximately 220 hours, roughly nine days, which is orders of magnitude longer than typical monoamine reuptake inhibitors that clear within a day. We present that number as what the secondary literature reports rather than as a measured value we can attribute to a single primary paper.

The practical consequence for study design is accumulation. With a half-life measured in days rather than hours, plasma concentration keeps climbing across repeated administrations in an animal model until steady state is reached, and reaching that steady state can take several weeks. Washout works the same way in reverse: clearing more than 99% of the compound requires roughly five to seven half-lives, which on a nine-day half-life means a washout window measured in weeks, not days.

Target engagement has been measured directly. A 2014 study in European Neuropsychopharmacology assessed dopamine transporter occupancy by positron emission tomography (PET) in the context of tesofensine's anti-obesity effects (PubMed). PET occupancy data is the gold standard here because it shows how much of the transporter population is actually bound, independent of plasma concentration.

This pharmacokinetic profile is why questions about repeat-exposure study designs and circadian timing variables in animal models come up constantly in tesofensine protocols. With a nine-day half-life, timing within a 24-hour window has far less influence on exposure than most researchers assume.

How do researchers verify a tesofensine vial before it enters a study?

Verification rests on three documents working together: a certificate of analysis (COA) tied to a specific lot, a high-performance liquid chromatography (HPLC) chromatogram establishing purity, and a mass spectrometry trace establishing identity. Purity without identity is meaningless, because a vial can be 99% pure something else entirely.

HPLC separates compounds by how long they take to pass through a column and reports purity as the percentage of total peak area attributable to the main peak. Research-grade material is typically specified at 98% or higher. Mass spectrometry answers the different question of what that peak is, by measuring the mass-to-charge ratio of the ionised molecule and comparing it against the expected molecular ion for tesofensine. A chromatogram alone proves homogeneity. The mass spec proves it's the right molecule.

Here's the failure mode we see most often, and it isn't a low purity number. It's a COA whose lot number doesn't match the number printed on the vial, or a COA with no lot number at all. A generic analysis certificate reused across every batch tells you about one historical sample and nothing about the vial on your bench. Check three fields before anything else: lot number matching the label, analysis date postdating the synthesis date, and the name of the testing laboratory.

Real Peptides supplies tesofensine for laboratory research with a published certificate of analysis for the lot. Researchers comparing documentation standards across suppliers often review guidance on buying tesofensine with a COA attached, what distinguishes a credible tesofensine supplier, and the narrower question of third-party testing standards in 2026.

What does correct laboratory handling and storage look like?

Tesofensine in solid form is stored cold, dark and dry, with long-term laboratory storage at −20°C and protection from light and moisture being the standard reference condition for research chemicals of this class. Once a solid is taken into solution, stability becomes a function of solvent, temperature, pH and the number of freeze-thaw cycles the vial experiences.

Freeze-thaw cycling is the handling error that quietly destroys more research material than contamination does. Each cycle introduces a temperature transition during which the compound spends time in solution at a temperature where degradation proceeds faster, and the damage is cumulative and invisible. Material that looks fine can be substantially degraded. Aliquoting on first preparation, so each working vial is thawed exactly once, eliminates the problem entirely.

Solvent choice matters more for tesofensine than for the peptides it's shelved beside. As a small molecule rather than a peptide, its solubility behaviour in aqueous versus organic solvents differs fundamentally, which is precisely why reconstitution errors occur when peptide handling habits get applied to it by default. Label every working vial with lot number, preparation date and solvent. A vial without provenance is a vial that can't be cited.

Is tesofensine legal to purchase, and what is its regulatory status?

Tesofensine holds no marketing authorisation from the U.S. Food and Drug Administration or the European Medicines Agency, and it is not an approved medicine in any major jurisdiction. It is supplied, lawfully, as a research chemical for laboratory investigation, which is a distinct regulatory category from a prescription drug and carries explicit restrictions on how the material may be used and described.

All compounds discussed on this page are sold for research use only and are not for human consumption.

That framing is not boilerplate. It's the condition under which tesofensine can be supplied at all. Research-use-only material is not manufactured under the same finished-drug-product controls as an approved medicine, has not been reviewed for any clinical indication, and carries none of the post-market surveillance infrastructure that approved drugs do. If an animal-health question is what brought you to this page, that conversation belongs with your veterinarian, not with a research-compound catalogue.

Regulations on importing and holding research chemicals vary by jurisdiction, and institutional policy frequently adds another layer on top of national law. Researchers reviewing logistics typically check shipping and service coverage before ordering, alongside general guidance on sourcing tesofensine online and shipping terms. Our team has walked a lot of labs through this step, and the pattern is consistent: the institutional policy check is the one most often skipped and the one most likely to stall a project.

How does tesofensine compare with related research compounds?

Tesofensine is routinely grouped with compounds that share an endpoint but share nothing mechanistically. This table sets out what each molecule actually is, what it targets, and how strong the published evidence base is, so the comparison is made on mechanism rather than marketing category.

Side-by-side breakdowns of each pairing are covered in depth in the 5-Amino-1MQ versus tesofensine comparison, the AOD-9604 versus tesofensine analysis, the cagrilintide comparison, and the difference between tesofensine and tirzepatide, which is the most frequently confused pairing of the lot.

What are the key takeaways?

• Tesofensine is a synthetic small molecule, not a peptide, despite being catalogued alongside peptides in research-chemical supply channels.
• It inhibits reuptake at the dopamine, noradrenaline and serotonin transporters simultaneously, which is what separates it from selective reuptake inhibitors.
• Its reported elimination half-life is approximately 220 hours in secondary pharmacology literature, roughly nine days, making accumulation and multi-week washout central to study design.
• The Lancet issued an expression of concern regarding the tesofensine obesity trial and published separate correspondence on under-reporting of adverse effects in that programme.
• Preclinical work reports appetite suppression via indirect alpha-1 adrenoceptor and dopamine D1 pathway stimulation, and silencing of GABAergic hypothalamic neurons.
• A usable research vial requires a lot-matched COA, an HPLC chromatogram above 98% purity, and a mass spectrometry identity confirmation.

What if: what do tesofensine laboratory scenarios look like?

What if the COA has no lot number on it?

Treat it as an undocumented vial and do not enter it into a study. A COA without a lot number cannot be tied to the material in front of you, which means the purity and identity figures on it describe some historical sample rather than your batch. Request the lot-specific certificate before the vial is opened, since an opened vial permanently weakens any later provenance argument.

What if the material was shipped at ambient temperature?

Record the transit conditions and transit duration in the study log before deciding anything. Solid research chemicals generally tolerate short ambient excursions far better than reconstituted solutions do, but the honest position is that you cannot verify integrity by appearance. If the study endpoint is sensitive, the defensible route is re-analysis rather than assumption.

What if two batches produce different results in the same animal model?

Compare the two chromatograms before changing anything about the experimental design. Batch-to-batch variance in impurity profile is a real and under-investigated source of divergent preclinical results, and a 98.2% batch and a 99.5% batch differ by more than the headline number suggests, because the identity of the remaining fraction differs too. Archive retained samples from both lots.

What is the uncomfortable truth about tesofensine's evidence base?

Here's the honest answer: tesofensine has a genuinely interesting mechanism and a genuinely compromised human evidence record, and anyone presenting one without the other is misrepresenting the literature. The preclinical work is real and mechanistically specific. The human obesity trial that made the compound famous carries a formal journal expression of concern and attracted published criticism for under-reporting adverse effects. Both things are true at once.

That combination is exactly why tesofensine remains a research compound rather than an approved medicine, and why every figure quoted from the trial literature should travel with its caveat attached.

How we researched this page

Every study claim on this page is linked to its PubMed record so you can read the abstract yourself, and we have described each source according to what its title and abstract actually state rather than what secondary coverage claims about it. The source set spans PLoS One, Obesity, Neuropsychopharmacology, Pharmacology, Biochemistry and Behavior, Archives of Neurology, European Neuropsychopharmacology, European Journal of Pharmacology, Current Opinion in Investigational Drugs and The Lancet, including the editorial correspondence record.

We make no first-party testing claims here. We did not run our own pharmacology on tesofensine, and nothing on this page should be read as original experimental data from us. Where a commonly repeated number could not be tied to a primary source we could link, we have labelled it as secondary-literature reporting rather than presenting it as established.

Further reading across the tesofensine research hub covers the mechanistic 5-Amino-1MQ comparison and the broader head-to-head on that pairing, the AOD-9604 mechanism and use-case breakdown alongside the fat-loss endpoint comparison, the literature on combining Semax with tesofensine in research settings, the appetite-suppression evidence summary, and the sourcing overview for tesofensine as a research compound.

Tesofensine is one of the few research compounds whose scientific story and whose publishing story are inseparable. A molecule discovered to affect body weight by accident, in trials designed for Parkinson's and Alzheimer's disease, that reached a major journal and then collected an expression of concern, is a case study in why mechanism and evidence quality have to be assessed independently. The hypothalamic and transporter-occupancy work still stands on its own. What doesn't stand is the habit of quoting the trial numbers as if the editorial record attached to them never happened.

References

Peer-reviewed sources on Tesofensine indexed in PubMed, listed for research context. Real Peptides supplies Tesofensine for laboratory research use only.

1. Tesofensine, a novel antiobesity drug, silences GABAergic hypothalamic neurons. PloS one, 2024. PMID 38656972. doi:10.1371/journal.pone.0300544
2. Anti-hypertensive treatment preserves appetite suppression while preventing cardiovascular adverse effects of tesofensine in rats. Obesity (Silver Spring, Md.), 2013. PMID 23784901. doi:10.1002/oby.20122
3. Tesofensine induces appetite suppression and weight loss with reversal of low forebrain dopamine levels in the diet-induced obese rat. Pharmacology, biochemistry, and behavior, 2013. PMID 23932919. doi:10.1016/j.pbb.2013.07.018
4. The effect of tesofensine on appetite sensations. Obesity (Silver Spring, Md.), 2012. PMID 21720440. doi:10.1038/oby.2011.197
5. Triple monoamine inhibitor tesofensine decreases food intake, body weight, and striatal dopamine D2/D3 receptor availability in diet-induced obese rats. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, 2012. PMID 21889317. doi:10.1016/j.euroneuro.2011.07.015
6. Subjective and objective effects of the novel triple reuptake inhibitor tesofensine in recreational stimulant users. Clinical pharmacology and therapeutics, 2010. PMID 20520602. doi:10.1038/clpt.2010.67
7. Tesofensine, a novel triple monoamine reuptake inhibitor, induces appetite suppression by indirect stimulation of alpha1 adrenoceptor and dopamine D1 receptor pathways in the diet-induced obese rat. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2010. PMID 20200509. doi:10.1038/npp.2010.16
8. The novel triple monoamine reuptake inhibitor tesofensine induces sustained weight loss and improves glycemic control in the diet-induced obese rat: comparison to sibutramine and rimonabant. European journal of pharmacology, 2010. PMID 20385125. doi:10.1016/j.ejphar.2010.03.026